Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2

被引:97
|
作者
Bluman, LG
Rimer, BK
Berry, DA
Borstelmann, N
Iglehart, JD
Regan, K
Schildkraut, J
Winer, EP
机构
[1] Dana Farber Canc Inst, Breast Oncol Ctr, Dept Care Coordinat, Boston, MA 02115 USA
[2] Dana Farber Canc Inst, Gillette Ctr Womens Canc, Boston, MA 02115 USA
[3] Duke Univ, Med Ctr, Canc Prevent Detect & Control Res Program, Durham, NC 27706 USA
[4] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27706 USA
[5] Duke Univ, Inst Stat & Decis Sci, Durham, NC 27706 USA
[6] NCI, Div Canc Control & Populat Sci, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1200/JCO.1999.17.3.1040
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: This study examined baseline knowledge, beliefs, and risk perceptions among a group of 200 women with breast and/or ovarian cancer who participated in a trial designed to improve decision making about genetic testing for BRCA1 and BRCA2. Patients and Methods: Women were identified by self-referral, physician referral, and tumor registry extraction and invited to participate in a randomized trial in which testing for BRCA I and BRCA2 was offered free of charge, Subjects completed baseline questionnaires and interviews that assessed knowledge, attitudes, and perceptions of risk of having an alteration in BRCA1 or BRCA2. Results: Sixty percent of women overestimated their chances of having a BRCA1 or BRCA2 mutation compared with estimates from a BRCA 1/BRCA2 risk model. Women who have at least three relatives with breast or ovarian cancer were one third (95% confidence interval, 0.2 to 0.6) as likely to overestimate their risk of having a BRCA1 or BRCA2 mutation compared with women who have two or fewer affected relatives. Knowledge wets limited about BRCA1 and BRCA2 mutations and cancer risk associated with gene mutations, Eighty-four percent of the women indicated a probable or definite interest in testing. Conclusion: A high proportion of the high-risk women in this study had knowledge deficits about BRCA1 and BRCA2 and overestimated their risk of having a mutation, Although some degree of caution should be used in generalizing the results of this study to practice settings, the data provide insight into the challenges clinicians will face in communicating with patients about cancer genetics. (C) 1999 by American Society of Clinical Oncology.
引用
收藏
页码:1040 / 1046
页数:7
相关论文
共 50 条
  • [31] Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations
    Moran, A.
    O'Hara, C.
    Khan, S.
    Shack, L.
    Woodward, E.
    Maher, E. R.
    Lalloo, F.
    Evans, D. G. R.
    [J]. FAMILIAL CANCER, 2012, 11 (02) : 235 - 242
  • [32] Association of Type and Location of BRCA1 and BRCA2 Mutations With Risk of Breast and Ovarian Cancer
    Rebbeck, Timothy R.
    Mitra, Nandita
    Wan, Fei
    Sinilnikova, Olga M.
    Healey, Sue
    McGuffog, Lesley
    Mazoyer, Sylvie
    Chenevix-Trench, Georgia
    Easton, Douglas F.
    Antoniou, Antonis C.
    Nathanson, Katherine L.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 313 (13): : 1347 - 1361
  • [33] Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations
    A. Moran
    C. O’Hara
    S. Khan
    L. Shack
    E. Woodward
    E. R. Maher
    F. Lalloo
    D. G. R. Evans
    [J]. Familial Cancer, 2012, 11 : 235 - 242
  • [34] IMPACT OF PREGNANCY ON THE RISK OF BREAST AND OVARIAN CANCER IN BRCA1 AND BRCA2 MUTATION CARRIERS
    Russo, M.
    Corvetto, E.
    Fais, M.
    Candotti, G.
    Locati, V.
    Proto, A.
    Angioni, S.
    Carcassi, C.
    Mais, V.
    Peiretti, M.
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A391 - A391
  • [35] Measuring women's preferences for breast cancer treatments and BRCA1/BRCA2 testing
    Cappelli, M
    Surh, L
    Humphreys, L
    Verma, S
    Logan, D
    Hunter, A
    Allanson, J
    [J]. QUALITY OF LIFE RESEARCH, 2001, 10 (07) : 595 - 607
  • [36] Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation
    Xia, Yue Yin
    Gronwald, Jacek
    Karlan, Beth
    Lubinski, Jan
    McCuaig, Jeanna M.
    Brooks, Jennifer
    Moller, Pal
    Eisen, Andrea
    Sun, Sophie
    Senter, Leigha
    Bordeleau, Louise
    Neuhausen, Susan L.
    Singer, Christian F.
    Tung, Nadine
    Foulkes, William D.
    Sun, Ping
    Narod, Steven A.
    Kotsopoulos, Joanne
    [J]. GYNECOLOGIC ONCOLOGY, 2022, 164 (03) : 514 - 521
  • [37] Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation
    Kotsopoulos, Joanne
    Gronwald, Jacek
    McCuaig, Jeanna M.
    Karlan, Beth Y.
    Eisen, Andrea
    Tung, Nadine
    Bordeleau, Louise
    Senter, Leigha
    Eng, Charis
    Couch, Fergus
    Fruscio, Robert
    Weitzel, Jeffrey N.
    Olopade, Olufunmilayo
    Singer, Christian F.
    Pal, Tuya
    Foulkes, William D.
    Neuhausen, Susan L.
    Sun, Ping
    Lubinski, Jan
    Narod, Steven A.
    Huzarski, Tomasz
    Cybulski, Cezary
    Rosen, Barry
    Sweet, Kevin
    Zakalik, Dana
    Wood, Marie
    McKinnon, Wendy
    Elser, Christine
    Wiesner, Georgia
    Friedman, Eitan
    Meschino, Wendy
    Snyder, Carrie
    Metcalfe, Kelly
    Poll, Aletta
    Warner, Ellen
    Kim, Raymond
    Armel, Susan
    Demsky, Rochelle
    Ainsworth, Peter
    Steele, Linda
    Saal, Howard
    Serfas, Kim
    Panchal, Seema
    Cullinane, Carey A.
    Reilly, Robert E.
    Blum, Joanne L.
    Kwong, Ava
    Rayson, Daniel
    Ramon y Cajal, Teresa
    Dungan, Jeffrey
    [J]. GYNECOLOGIC ONCOLOGY, 2020, 159 (03) : 820 - 826
  • [38] BRCA1 and BRCA2 Mutations in Women of Different Ethnicities Undergoing Testing for Hereditary Breast-Ovarian Cancer
    Hall, Michael J.
    Reid, Julia E.
    Burbidge, Lynn A.
    Pruss, Dmitry
    Deffenbaugh, Amie M.
    Frye, Cynthia
    Wenstrup, Richard J.
    Ward, Brian E.
    Scholl, Thomas A.
    Noll, Walter W.
    [J]. CANCER, 2009, 115 (10) : 2222 - 2233
  • [39] Measuring women's preferences for breast cancer treatments and BRCA1/BRCA2 testing
    M. Cappelli
    L. Surh
    L. Humphreys
    S. Verma
    D. Logan
    A. Hunter
    J. Allanson
    [J]. Quality of Life Research, 2001, 10 : 595 - 607
  • [40] Risk of ovarian cancer in BRCA1 and BRCA2 mutation negative hereditary breast cancer families
    Kauff, ND
    Mitra, N
    Robson, ME
    Hurley, KE
    Chuai, S
    Goldfrank, D
    Wadsworth, E
    Lee, J
    Cigler, T
    Borgen, PI
    Norton, L
    Barakat, RR
    Offit, K
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (18) : 1382 - 1384